RU93005089A - MANUFACTURING HUMAN PROTEIN, DNA, CELL, PHARMACEUTICAL COMPOSITION, USE OF DERIVATIVE PROTEIN C, METHOD OF OBTAINING - Google Patents
MANUFACTURING HUMAN PROTEIN, DNA, CELL, PHARMACEUTICAL COMPOSITION, USE OF DERIVATIVE PROTEIN C, METHOD OF OBTAININGInfo
- Publication number
- RU93005089A RU93005089A RU93005089/13A RU93005089A RU93005089A RU 93005089 A RU93005089 A RU 93005089A RU 93005089/13 A RU93005089/13 A RU 93005089/13A RU 93005089 A RU93005089 A RU 93005089A RU 93005089 A RU93005089 A RU 93005089A
- Authority
- RU
- Russia
- Prior art keywords
- protein
- dna
- obtaining
- cell
- pharmaceutical composition
- Prior art date
Links
- 229920003013 deoxyribonucleic acid Polymers 0.000 title claims 2
- 102000004169 proteins and genes Human genes 0.000 title 2
- 108090000623 proteins and genes Proteins 0.000 title 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000004913 activation Effects 0.000 claims 2
- NKCXQMYPWXSLIZ-PSRDDEIFSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-m Chemical compound O=C([C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NKCXQMYPWXSLIZ-PSRDDEIFSA-N 0.000 claims 1
- 102000003839 Human Proteins Human genes 0.000 claims 1
- 108090000144 Human Proteins Proteins 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000005714 functional activity Effects 0.000 claims 1
- 101500017928 human Saposin-D Proteins 0.000 claims 1
- 229940100689 human protein C Drugs 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
Claims (1)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88719192A | 1992-05-21 | 1992-05-21 | |
US07/887,191 | 1992-05-21 | ||
US07/887.191 | 1992-05-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU93005089A true RU93005089A (en) | 1996-03-10 |
RU2122004C1 RU2122004C1 (en) | 1998-11-20 |
Family
ID=25390640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU93005089A RU2122004C1 (en) | 1992-05-21 | 1993-05-19 | Derivative of human c-protein and a pharmaceutical composition showing antithrombic effect |
Country Status (23)
Country | Link |
---|---|
US (1) | US5453373A (en) |
EP (1) | EP0575054B1 (en) |
JP (1) | JP3564150B2 (en) |
KR (1) | KR100291529B1 (en) |
CN (1) | CN1080658A (en) |
AT (1) | ATE286121T1 (en) |
AU (1) | AU661901B2 (en) |
BR (1) | BR9301944A (en) |
CA (1) | CA2096604C (en) |
CZ (1) | CZ286016B6 (en) |
DE (1) | DE69333727T2 (en) |
DK (1) | DK0575054T3 (en) |
ES (1) | ES2233925T3 (en) |
FI (1) | FI932282A (en) |
HU (1) | HU218408B (en) |
IL (1) | IL105757A0 (en) |
MX (1) | MX9302917A (en) |
MY (1) | MY110664A (en) |
NO (1) | NO311299B1 (en) |
NZ (1) | NZ247651A (en) |
PH (1) | PH29911A (en) |
PT (1) | PT575054E (en) |
RU (1) | RU2122004C1 (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2067525C (en) * | 1991-05-09 | 1998-09-15 | Helmut G. Alt | Organometallic fluorenyl compounds, preparation and use |
AT402262B (en) * | 1991-06-20 | 1997-03-25 | Immuno Ag | MEDICINAL ACTIVATED PROTEIN C |
US5716795A (en) * | 1991-10-04 | 1998-02-10 | Matschiner; John T. | Thrombomodulin-based coagulometric assay of the protein C system |
AU2870992A (en) * | 1991-10-04 | 1993-05-03 | Board Of Regents Of The University Of Nebraska, The | A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins |
DE4320294A1 (en) * | 1993-06-18 | 1994-12-22 | Immuno Ag | Use of human protein C to prevent and treat platelet deposits |
US6630137B1 (en) | 1997-04-28 | 2003-10-07 | Eli Lilly And Company | Activated protein C formulations |
HU224826B1 (en) | 1997-04-28 | 2006-02-28 | Lilly Co Eli | Activated protein c formulations |
ZA984698B (en) * | 1997-06-05 | 2000-02-01 | Lilly Co Eli | Methods for treating thombotic disorders. |
HUP0001237A3 (en) * | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
JP2003506006A (en) * | 1998-07-31 | 2003-02-18 | イーライ・リリー・アンド・カンパニー | Cold granulation of activated protein C |
US6815533B1 (en) | 1998-07-31 | 2004-11-09 | Eli Lilly And Company | Cryogranulation of activated protein C |
CN1324244A (en) | 1998-10-22 | 2001-11-28 | 伊莱利利公司 | Methods for treating sepsis |
CA2351067A1 (en) | 1998-11-13 | 2000-05-25 | Eli Lilly And Company | Method of treating heparin-induced thrombocytopenia |
ES2195655T3 (en) | 1998-11-20 | 2003-12-01 | Lilly Co Eli | PROCEDURE TO TREAT VIRIC HEMORRAGICAL FEVER WITH PROTEIN C. |
BR9915572A (en) | 1998-11-23 | 2001-08-14 | Lilly Co Eli | Process of treatment of sickle cell disease and thalassemia |
US6998122B1 (en) * | 1999-04-30 | 2006-02-14 | Eli Lilly And Company | Protein C derivatives |
JP2003514545A (en) * | 1999-11-19 | 2003-04-22 | イーライ・リリー・アンド・カンパニー | Protein C derivative |
ES2234807T3 (en) * | 2000-02-02 | 2005-07-01 | Eli Lilly And Company | DERIVATIVES OF PROTEIN C. |
EP1263943A1 (en) * | 2000-02-11 | 2002-12-11 | Eli Lilly & Company | Protein c derivatives |
US7204981B2 (en) * | 2000-03-28 | 2007-04-17 | Eli Lilly And Company | Methods of treating diseases with activated protein C |
US6933367B2 (en) | 2000-10-18 | 2005-08-23 | Maxygen Aps | Protein C or activated protein C-like molecules |
KR20030060915A (en) * | 2000-10-18 | 2003-07-16 | 맥시겐 에이피에스 | Protein c or activated portein c-like molecules |
IL154999A0 (en) * | 2000-10-18 | 2003-10-31 | Maxygen Aps | Protein c or activated protein c-like molecules |
US20040198652A1 (en) * | 2001-04-24 | 2004-10-07 | Carter J. Paul | Methods and compositions for preventing and treating septic shock and endotoxemia |
AU2003213146A1 (en) * | 2002-03-08 | 2003-09-22 | Eli Lilly And Company | Activated protein c formulations |
WO2003106666A2 (en) * | 2002-06-14 | 2003-12-24 | Maxygen Aps | Protein c variants with altered properties |
US20070142272A1 (en) * | 2003-01-24 | 2007-06-21 | Zlokovic Berislav V | Neuroprotective activity of activated protein c independent of its anticoagulant activity |
WO2006014839A2 (en) * | 2004-07-23 | 2006-02-09 | The University Of Rochester | Activated protein c inhibits undesirable effects of plasminogen activator in the brain |
EP1913155A4 (en) * | 2005-06-23 | 2009-08-12 | Univ British Columbia | Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy |
EP2041338A4 (en) * | 2006-06-09 | 2009-09-30 | Univ British Columbia | Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects |
EP2178556B1 (en) * | 2007-06-18 | 2011-08-17 | Oregon Health & Science University | Protein c for use in maintaining hemostasis |
US20110171200A1 (en) * | 2008-01-15 | 2011-07-14 | Walley Keith R | Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound |
CN104262479A (en) | 2008-12-19 | 2015-01-07 | 国家健康与医学研究院 | Serine Protease Derivatives And Uses In The Prevention Or The Treatment Of Blood Coagulation Disorders |
WO2012068519A2 (en) | 2010-11-19 | 2012-05-24 | Sirius Genomics Inc. | Markers associated with response to activated protein c administration, and uses thereof |
US20150150954A1 (en) | 2012-07-04 | 2015-06-04 | The University Of Sydney | Treatment of inflammatory skin disorders |
DK3137102T3 (en) | 2014-04-16 | 2021-10-11 | Zz Biotech Llc | APC FOR USE FOR THE TREATMENT OF ABNORMAL CUTANE FORMATION |
WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4775624A (en) * | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
US4992373A (en) * | 1987-12-04 | 1991-02-12 | Eli Lilly And Company | Vectors and compounds for direct expression of activated human protein C |
ZA889497B (en) * | 1987-12-28 | 1990-08-29 | Lilly Co Eli | Vectors and compounds for expression of zymogen forms of human protein c |
US4981952A (en) * | 1988-10-04 | 1991-01-01 | Eli Lilly And Company | Method for the purification of vitamin K-dependent proteins |
US5270178A (en) * | 1990-02-23 | 1993-12-14 | Eli Lilly And Company | Vectors and compounds for expression of zymogen forms of human protein C |
IL97311A0 (en) * | 1990-02-23 | 1992-05-25 | Lilly Co Eli | Vectors and compounds for expression of glycosylation mutants of human protein c |
-
1993
- 1993-05-18 MY MYPI93000913A patent/MY110664A/en unknown
- 1993-05-19 AT AT93303894T patent/ATE286121T1/en not_active IP Right Cessation
- 1993-05-19 PT PT93303894T patent/PT575054E/en unknown
- 1993-05-19 EP EP93303894A patent/EP0575054B1/en not_active Expired - Lifetime
- 1993-05-19 DK DK93303894T patent/DK0575054T3/en active
- 1993-05-19 CZ CZ93948A patent/CZ286016B6/en not_active IP Right Cessation
- 1993-05-19 DE DE69333727T patent/DE69333727T2/en not_active Expired - Fee Related
- 1993-05-19 NZ NZ247651A patent/NZ247651A/en unknown
- 1993-05-19 KR KR1019930008613A patent/KR100291529B1/en not_active IP Right Cessation
- 1993-05-19 NO NO19931840A patent/NO311299B1/en not_active IP Right Cessation
- 1993-05-19 FI FI932282A patent/FI932282A/en unknown
- 1993-05-19 CA CA002096604A patent/CA2096604C/en not_active Expired - Fee Related
- 1993-05-19 HU HU9301461A patent/HU218408B/en not_active IP Right Cessation
- 1993-05-19 ES ES93303894T patent/ES2233925T3/en not_active Expired - Lifetime
- 1993-05-19 RU RU93005089A patent/RU2122004C1/en active
- 1993-05-19 MX MX9302917A patent/MX9302917A/en unknown
- 1993-05-20 PH PH46212A patent/PH29911A/en unknown
- 1993-05-20 CN CN93106214A patent/CN1080658A/en active Pending
- 1993-05-20 IL IL105757A patent/IL105757A0/en unknown
- 1993-05-20 JP JP11822393A patent/JP3564150B2/en not_active Expired - Fee Related
- 1993-05-20 AU AU38699/93A patent/AU661901B2/en not_active Ceased
- 1993-05-20 BR BR9301944A patent/BR9301944A/en not_active Application Discontinuation
- 1993-07-09 US US08/089,215 patent/US5453373A/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU93005089A (en) | MANUFACTURING HUMAN PROTEIN, DNA, CELL, PHARMACEUTICAL COMPOSITION, USE OF DERIVATIVE PROTEIN C, METHOD OF OBTAINING | |
NO890921D0 (en) | PROCEDURE FOR THE PREPARATION OF AMINO ACID DERIVATIVES. | |
NO882732D0 (en) | PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE AMINO ACID DERIVATIVES. | |
FR2629825B1 (en) | NOVEL PEPTIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | |
ATA285187A (en) | SUBSTITUTED ALPHA AMINO ACIDS, THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THEM | |
NO873699D0 (en) | POLYPEPTIDE SUITABLE FOR DIMENSION, TREATMENT AND DIAGNOSIS OF AUTOIMMUNE DISEASES SUCH AS ARTICLES. | |
NO871295D0 (en) | PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE AMINO ACID DERIVATIVES. | |
IT8647666A0 (en) | PEPTIDES AND PEPTIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | |
RU94041224A (en) | PEPTIDES WITH ORGAN-PROTECTIVE ACTIVITY, PHARMACEUTICAL COMPOSITION ON THEIR BASIS AND THEIR USE IN THERAPY | |
CA2114313A1 (en) | Bpc peptides, their preparation and use | |
FR2694296B1 (en) | Peptides inhibiting the activity of ras proteins, preparation and use. | |
NO870049D0 (en) | PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE AMINO ACID DERIVATIVES. | |
NO165071C (en) | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 7- (3-AMINO-1-PYRROLIDINYL) -8-CHLORO-1-CYCLOPROPYL-6-FLUORO-1,4, -DIHYDRO-4-OXO-3-CHINOLINE-CARBOXYL. | |
NO166326C (en) | PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 3,7-SUBSTITUTED-8-OXO-5-THIA-1-AZABICYCLO- (4,2,0) OCT-2-EN-2-CARBOXYLATER. | |
NO863373D0 (en) | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE AMINO ACID DERIVATIVES. | |
DE68917837D1 (en) | Peptide compounds. | |
FI892684A (en) | Process for the preparation of therapeutically active 4-oxoimidazo [1,5-a] quinoxaline derivatives | |
DE68907392T2 (en) | Dysmnesia modifying drugs. | |
NO893794L (en) | PROCEDURE FOR THE PREPARATION OF IMPROVED HYDROLYZEATED PROTEIN. | |
ATE90359T1 (en) | PEPTIDES. | |
IT8819791A0 (en) | PEPTIDES WITH PHARMACEUTICAL ACTIVITY. | |
EP0780472A3 (en) | Stress proteins | |
NO166280C (en) | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE N, N'-DISUBSTITUTED UREA. | |
NO172491C (en) | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 1,3-DIOXANE-ALCOHIC ACID DERIVATIVES | |
FI894812A0 (en) | Process for the preparation of pharmacologically valuable 2-carbonyl-substituted N, N'-di (trimethoxybenzoyl) piperazines |